study leader gerald andriole said it "may potentially offer many thousands of men a way to reduce their risk of being diagnosed with prostate cancer."
andriole, who is the chief of urologic surgery at washington university school of medicine in st. louis, added, "this means more men could avoid unnecessary treatment for prostate cancer along with the costs and harmful side effects that can occur with treatment."
the four-year-long study was conducted on some 8,231 men aging from 50 to 75, who were randomly given either a placebo or a daily dose of the drug.?
